BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37001548)

  • 21. Role of adjuvant chemotherapy after concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
    Kou L; Zhang T; Yang X; Peng S; Wang Y; Yuan M; Li M
    Future Oncol; 2022 May; 18(16):1917-1915. PubMed ID: 35193379
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of a treatment in patients with locoregionally advanced nasopharyngeal carcinoma (LANC) involving carotid artery invasion.
    Liu K; Wang Y; Ma L; Yang S; Zhang X
    Eur Arch Otorhinolaryngol; 2022 Dec; 279(12):5791-5799. PubMed ID: 35918541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
    Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
    Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer.
    Li J; Li Y; Wang H; Shen L; Wang Q; Shao S; Shen Y; Xu H; Liu H; Cai R; Feng W
    BMC Cancer; 2023 Jan; 23(1):51. PubMed ID: 36641433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer.
    Chen W; Li T; Wang J; Liang L; Huang D; Yan G; Tian Y; Zhang X; Zhang W
    Cancer Manag Res; 2019; 11():8157-8165. PubMed ID: 31564975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma.
    Wang RJ; Ke RQ; Yu YF; Lu GZ; Wu SG
    Front Pharmacol; 2024; 15():1366853. PubMed ID: 38576484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery.
    Yang J; Yang J; Cao D; Shen K; Ma J; Zhang F
    J Gynecol Oncol; 2020 Mar; 31(2):e16. PubMed ID: 31912674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
    You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
    Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effects of Different Chemoradiotherapy Regimens on Early Survival Outcomes in Patients with Locally Advanced Nasopharyngeal Carcinoma].
    Li N; Li P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Sep; 51(5):702-707. PubMed ID: 32975088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
    Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
    Kim YI; Park JW; Kim BH; Woo SM; Kim TH; Koh YH; Lee WJ; Kim CM
    Radiat Oncol; 2013 Dec; 8():292. PubMed ID: 24359879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
    Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis.
    Fu ZZ; Li K; Peng Y; Zheng Y; Cao LY; Zhang YJ; Sun YM
    Medicine (Baltimore); 2017 Jan; 96(2):e5853. PubMed ID: 28079819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.
    Tian X; Xuan Y; Wu R; Gao S
    Cancer Manag Res; 2020; 12():3323-3329. PubMed ID: 32494195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
    Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
    Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
    Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Mu X; Liu H; Wu J; Chen S; Peng X; Wang J; Wei Z; He L; Liu J; Lu Z; Su Y
    Aging (Albany NY); 2022 Aug; 14(16):6727-6739. PubMed ID: 36036759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.